Cancer Screening and Prevention

Cancer screening and prevention covers the primary-care activities that reduce cancer deaths by lowering exposure to causes (prevention) and by detecting cancer or its precursors early in people without symptoms (screening). It rests on the principle that earlier detection is worthwhile only when it changes the disease course, and it balances the benefits of screening against harms such as false positives and overdiagnosis.

Definition

Cancer screening and prevention comprises interventions that reduce cancer incidence by addressing causes and that detect cancer or precancerous lesions in asymptomatic people early enough to reduce cancer mortality, weighed against the harms of testing.

Scope

The topic covers the rationale for organised cancer screening, the major programmes encountered in primary care (such as colorectal, lung, breast, and cervical screening), and the recurring trade-offs of sensitivity, specificity, and overdiagnosis. It treats cancer screening as a reference and educational subject, summarising how the evidence is appraised rather than prescribing who should be screened, which depends on individual risk and current guidelines.

Core questions

• For which cancers does screening reduce mortality enough to justify its harms?
• How are the benefits of earlier detection separated from lead-time and length-time bias?
• How should overdiagnosis — finding cancers that would never have caused harm — be balanced against the lives screening saves?

Key concepts

• Screening versus diagnostic testing
• Sensitivity, specificity, and predictive value
• Detection of precursor lesions
• Lead-time and length-time bias
• Overdiagnosis and overtreatment
• Mortality reduction as the key endpoint
• Risk-based eligibility (for example smoking history for lung screening)
• Organised versus opportunistic screening

Mechanisms

Cancer screening interrupts the natural history of malignancy at two points. By detecting precursor lesions — such as colorectal adenomas or cervical dysplasia — and removing them, screening can prevent invasive cancer from developing (a primary-prevention effect of a secondary-prevention tool). By detecting invasive cancer at an earlier, more treatable stage, it can reduce cancer-specific mortality. Whether either effect occurs depends on the disease having a detectable preclinical phase during which treatment is more effective. The value of a programme is judged chiefly by reductions in disease-specific or all-cause mortality in randomised or high-quality observational evidence, because earlier diagnosis alone can appear beneficial through lead-time bias, and indolent disease can be preferentially detected through length-time bias. Screening also detects cancers that would never have become clinically significant — overdiagnosis — leading to overtreatment, which is the principal harm to weigh against benefit.

Clinical relevance

Offering, explaining, and arranging cancer screening is a frequent task in family medicine, and clinicians help patients weigh benefits against harms in shared decisions. Recommendation bodies grade which screens have net benefit and for whom. This entry summarises that reasoning for educational reference; it is not a schedule of who should be screened or how, which depends on individual risk factors, age, and current guidelines.

Epidemiology

Cancer is a leading cause of death worldwide, with global estimates describing millions of new cases and deaths annually across many cancer types. Several of the most common and lethal cancers — including colorectal, lung, breast, and cervical cancer — have screening tests with evidence of mortality benefit in defined populations, which is why they feature prominently in primary-care prevention.

Evidence & guidelines

The US Preventive Services Task Force issues evidence-graded screening recommendations, including for colorectal cancer and for lung cancer using low-dose CT in adults with a sufficient smoking history, each accompanied by systematic evidence reviews. Other bodies provide breast and cervical screening guidance. Eligibility criteria, intervals, and modalities are revised as evidence accrues, so any specific recommendation should be checked against its current version.

History

Population cancer screening expanded through the second half of the twentieth century, beginning with cervical cytology (the Papanicolaou test) and later mammography, faecal and endoscopic colorectal testing, and, more recently, low-dose CT screening for lung cancer in high-risk groups. As programmes matured, attention shifted from simply detecting more cancers to demonstrating mortality benefit and quantifying harms such as overdiagnosis, shaping the risk-based, evidence-graded approach used today.

Debates

Overdiagnosis in cancer screening

Screening can detect cancers that would never have caused symptoms or death, leading to treatment that carries harm without benefit; estimating the extent of overdiagnosis and weighing it against lives saved is contested across breast, prostate, and lung screening.

Seminal works

• uspstf-colorectal-2021
• uspstf-lung-2021
• lin-2021

Frequently asked questions

Why are only some cancers screened for?

Screening is recommended only where there is good evidence that detecting the cancer earlier reduces deaths and that the benefits outweigh harms like false positives and overdiagnosis. Many cancers lack a test that meets these conditions.

What is overdiagnosis in cancer screening?

Overdiagnosis is the detection of a cancer that would never have caused symptoms or death in the person's lifetime. Because such cancers are usually treated anyway, overdiagnosis exposes people to the harms of treatment without benefit, and it is a key harm weighed against the lives screening saves.